About Pricing FAQs Providers Trials Blog

Back to your record

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Lymphoma Clinical Trials in Minneapolis | 229 Studies

Clinical Trials LymphomaMinneapolis

Lymphoma Clinical Trials in Minneapolis

Find 229 clinical trials for lymphoma near Minneapolis, Minnesota. Connect with research centers in your area.

All Lymphoma trials nationwide All trials in Minneapolis

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4Not applicable

Who can join

Healthy volunteers too

Showing 181-200 of 229 trials

CompletedSafety & Efficacy Study of AT-101 in Combination w/ Rituximab in Previously Untreated Grade I-II Follicular Non-Hodgkin's LymphomaThis is a phase II clinical trial in patients who have not received systemic treatment for follicular non-Hodgkin's lymphoma.NCT00440388·Birmingham, Alabama and 27 others CompletedA Study of Oral LY317615 in Relapsed or Refractory Diffuse Large B-Cell Lymphomas.This study will measure the effectiveness and any side effects of LY317615 in participants with diffuse large B-cell lymphoma (DLBCL: a sub-type of Non-Hodgkins Lymphoma).NCT00042666·Royal Oak, Michigan and 2 others

Lymphoma Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

CompletedNKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin LymphomaPatients will receive intravenous (IV) NKTR-255 in 21 or 28 day treatment cycles.NCT04136756·Goodyear, Arizona and 12 others

CompletedCombination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic LeukemiaRATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.NCT00002494·La Jolla, California and 22 others

CompletedBevacizumab and Combination Chemotherapy in Treating Patients With Peripheral T-Cell Lymphoma or Natural Killer Cell NeoplasmsRATIONALE: Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.NCT00217425·Greenbrae, California and 109 others

TerminatedOpen-Label Extension Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered in Participants With B-cell NHLThis is an open-label extension study enrolling participants experiencing clinical benefit following 6 cycles of DI-Leu16-IL2 while enrolled in the Alopexx Oncology…NCT02151903·Duarte, California and 2 others

CompletedA Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell LymphomaStudy of ONTAK and CHOP (chemotherapy drugs) to find out their ability to make Peripheral T-cell lymphoma disappear (for any period of time) and potentially lengthen life.NCT00211185·Birmingham, Alabama and 48 others

CompletedIrinotecan in Treating Patients With Solid Tumors or Lymphoma Who Have Abnormal Liver or Kidney Function or Who Have Received Radiation Therapy to the PelvisRATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.NCT00003368·Birmingham, Alabama and 44 others

TerminatedTrial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's LymphomaThe primary objectives of this study are: * To investigate the safety and tolerability, and to define the recommended Phase 2 dose and schedule (RP2DS) for magrolimab in…NCT02953509·Birmingham, Alabama and 19 others

CompletedStudy Evaluating Two Dose Levels of Targretin Capsules in Participants With Refractory Cutaneous T-Cell Lymphoma (CTCL)This is a multicenter, randomized, open-label, Phase IV study to assess the efficacy, tolerability, and safety of 2 initial dose levels of bexarotene capsules in participants with…NCT01007448·Birmingham, Alabama and 16 others

TerminatedRituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System LymphomaRATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and kill them or carry cancer-killing substances to them.NCT00335140·Stanford, California and 67 others

CompletedRituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin's Lymphoma That is Not Refractory to RituximabMonoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.NCT00238238·La Jolla, California and 78 others

Active not recruitingErdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)This phase II Pediatric MATCH trial studies how well erdafitinib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with FGFR mutations…NCT03210714·Birmingham, Alabama and 115 others

CompletedCombination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell LymphomaRATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.NCT00006747·Birmingham, Alabama and 47 others

TerminatedA Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin LymphomaThe purpose of this study is to assess the safety, tolerability, drug levels, and preliminary efficacy of relatlimab plus nivolumab in pediatric and young adult participants with…NCT05255601·Birmingham, Alabama and 50 others

WithdrawnA Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i TherapiesThe purpose of this study is to compare the efficacy and safety of liso-cel vs Investigator's Choice options (idelalisib + rituximab or bendamustine + rituximab) in adult…NCT06205290·Gilbert, Arizona and 47 others

TerminatedQUILT-3.002: N-803 in Patients With Relapse/Refractory iNHL in Conjunction With RituximabThis is a Phase I/II, open-label, multi-center, competitive enrollment and dose escalation study of N-803 in patients with relapse/refractory indolent B cell non-Hodgkin lymphoma…NCT02384954·Minneapolis, Minnesota and 3 others

TerminatedA Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid TumorsThis study will evaluate the efficacy and safety of alectinib in participants with Anaplastic Lymphoma Kinase (ALK)-positive locally advanced or metastatic solid tumors other than…NCT04644315·Culver City, California and 28 others

CompletedRituximab and Galiximab in Treating Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's LymphomaRATIONALE: Monoclonal antibodies, such as rituximab and galiximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.NCT00117975·Washington D.C., District of Columbia and 67 others

CompletedSafety and Tolerability of HSC835 in Patients With Hematological Malignancies Undergoing Single Umbilical Cord Blood TransplantThis study was designed to evaluate the safety and tolerability of HSC835 for clinical use as measured by the absence of graft failure at day 42 in excess of that currently…NCT01930162·Minneapolis, Minnesota

PreviousPage 10 of 12Next

Other Conditions in Minneapolis

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia